Imagion Biosystems Limited has announced a supplementary prospectus (Supplementary Prospectus) which shall be read with the prospectus dated 28 October 2019 (Prospectus) and issued by Imagion Biosystems Limited (Company or IBX).
Read the supplementary prospectus.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)